SABCS Roundtable with Dr. Howard Burris and Dr. William Gradishar

SAN ANTONIO – Perspectives on IBIS-II, dasatinib in combination with leutrozole, dual pathway blockade, CDK inhibitors, and more practice-changing trial results from the San Antonio Breast Cancer Symposium are discussed by Dr. Howard A. Burris, III, Chief Medical Officer and Director of Drug Development at the Sarah Cannon Research Institute, Nashville, Tenn.; and Dr. William A. Gradishar, Betsy Bramsen Professor of Breast Oncology at the Northwestern University Feinberg School of Medicine, Director of the Maggie Daley Center For Women's Cancer Care, and a member of the Robert H. Lurie Comprehensive Cancer Center, Chicago.

SAN ANTONIO – Perspectives on IBIS-II, dasatinib in combination with leutrozole, dual pathway blockade, CDK inhibitors, and more practice-changing trial results from the San Antonio Breast Cancer Symposium are discussed by Dr. Howard A. Burris, III, Chief Medical Officer and Director of Drug Development at the Sarah Cannon Research Institute, Nashville, Tenn.; and Dr. William A. Gradishar, Betsy Bramsen Professor of Breast Oncology at the Northwestern University Feinberg School of Medicine, Director of the Maggie Daley Center For Women's Cancer Care, and a member of the Robert H. Lurie Comprehensive Cancer Center, Chicago.

SAN ANTONIO – Perspectives on IBIS-II, dasatinib in combination with leutrozole, dual pathway blockade, CDK inhibitors, and more practice-changing trial results from the San Antonio Breast Cancer Symposium are discussed by Dr. Howard A. Burris, III, Chief Medical Officer and Director of Drug Development at the Sarah Cannon Research Institute, Nashville, Tenn.; and Dr. William A. Gradishar, Betsy Bramsen Professor of Breast Oncology at the Northwestern University Feinberg School of Medicine, Director of the Maggie Daley Center For Women's Cancer Care, and a member of the Robert H. Lurie Comprehensive Cancer Center, Chicago.